BioSpace News Archive

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced its operating and financial results for the first quarter of 2020.

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced financial results for the first quarter ended March 31, 2020 and provided an update on its clinical development programs.

Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reports its financial results and corporate update for the first quarter ended March 31, 2020.

Cigna has taken bold actions throughout the COVID-19 pandemic to make it easier and more affordable for customers to access the care they need to fight the virus and prevent its spread.

Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, reviewed recent business highlights and reported financial results for the first quarter ended March 31, 2020.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received CE mark approval for the Senza® Omnia™ Spinal Cord Stimulation (SCS) system.

The international medical imaging IT and cybersecurity company Sectra will publish its year-end report for the 2019/2020 fiscal year on June 3, 2020.

There are players operating in the global medical imaging information system market, for example, Varian Medical Systems, Hitachi, Mindray Medical, Toshiba, Siemens Healthcare, GE Healthcare, Fujifilm, Philips, Hologic, Neusoft Medical Systems, and Esaote.

Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health announced the initiation of a controlled clinical study evaluating Microbiome Metabolic Therapy candidate KB109 added to Supportive Self-Care for outpatients who are positive for SARs-Cov-2 infection with mild-to-moderate COVID-19.